Revelation Biosciences, Inc.
REVB
$2.92
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.92% | -14.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.38% | -28.77% | |||
| Operating Income | 2.38% | 28.77% | |||
| Income Before Tax | 23.01% | 73.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.01% | 73.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.01% | 73.28% | |||
| EBIT | 2.38% | 28.77% | |||
| EBITDA | 2.39% | 28.85% | |||
| EPS Basic | 62.79% | 83.70% | |||
| Normalized Basic EPS | 62.79% | 83.70% | |||
| EPS Diluted | 62.94% | 83.63% | |||
| Normalized Diluted EPS | 62.79% | 83.70% | |||
| Average Basic Shares Outstanding | 106.87% | 63.89% | |||
| Average Diluted Shares Outstanding | 106.87% | 63.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||